Get started
Author

M.R. García-Campelo

Observed names: M. Garcia-Campelo, M. R. Garcia-Campelo, M. R. García-Campelo, M. Rosario Garcia-Campelo, M. Rosario García-Campelo, M.-R. García-Campelo, M.R. Garcia-Campelo, M.d.R. García- Campelo, Maria Rosario García-Campelo, Maria Rosario García‐Campelo, María Rosario García-Campelo
ORCID: 0000-0002-5067-7533
Observed ORCID: 0000-0002-5067-7533
OpenAlex ID: A5110240875
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
2020 · Mariano Provencio, Ernest Nadal, et al. · The Lancet Oncology · 930
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022 · Mariano Provencio, Roberto Serna-Blasco, et al. · Journal of Clinical Oncology · 386
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
2021 · Renata Ferrarotto, Ian Anderson, et al. · Cancer Medicine · 50
PDF
Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)
2012 · R. Rosell, B. Massuti Sureda, et al. · Annals of Oncology · 17
LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
2023 · A. Passaro, B.C. Cho, et al. · Annals of Oncology · 16
PDF
LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
2023 · A.R.R. Filippi, M.R. García-Campelo, et al. · Annals of Oncology · 13
PDF
Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis
2024 · Igor Gomez-Randulfe, Sofía Silva Díaz, et al. · Therapeutic Advances in Medical Oncology · 12
A phase II single-arm study of LDK378 in patients with ALK-activated (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
2013 · Alice Tsang Shaw, Tony Mok, et al. · Journal of Clinical Oncology · 8
1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
2023 · E. Felip, M.G. Krebs, et al. · Annals of Oncology · 6
PDF
LBA51 Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial
2024 · A.R. Filippi, M.R. Garcia-Campelo, et al. · Annals of Oncology · 4
PDF
1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
2023 · M.D. Isla Casado, E. Arriola, et al. · Annals of Oncology · 4
PDF
1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
2023 · M.R. García-Campelo, M. Dómine, et al. · Annals of Oncology · 4
ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
2019 · E. Felip, B. Besse, et al. · Annals of Oncology · 4
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
2017 · J. Remon, D. Isla, et al. · Clinical & Translational Oncology · 4
Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
2019 · R. Laza-Briviesca, A. Cruz-Bermudez, et al. · Annals of Oncology · 3
Tobacco use in lung cancer (LC) patients (p) in Spain
2019 · E. Carcereny Costa, M. Guirado, et al. · Annals of Oncology · 3
Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.
2012 · Blanca Cantos, Margarita Majem, et al. · Journal of Clinical Oncology · 3
P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain
2022 · B. Massutí, E. Nadal, et al. · Journal of Thoracic Oncology · 1
PDF
Biomarker testing of lung cancer in Spain
2019 · D. Rodriguez Abreu, M. Guirado, et al. · Annals of Oncology · 1
Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients.
2013 · Trever Grant Bivona, Petros Giannikopoulos, et al. · Journal of Clinical Oncology · 1
MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations.
2012 · M. Rosario Garcia-Campelo, Miquel Taron, et al. · Journal of Clinical Oncology · 1
Small cell lung cancer in women: The Spanish female-specific database WORLD07.
2010 · N. Vinolas, D. Isla, et al. · Journal of Clinical Oncology · 1
P3.421: A Pulmón - Lunging It: Climbing Mountains and Breaking Barriers in Lung Cancer Advocacy — Updated Nationwide Results
2026 · S. Viteri, A. Urtasun, et al. · Journal of Thoracic Oncology
Challenges in the measurement and valuation of oncological treatments in Spain: recommendations and call to action
2026 · Maria Rosario García-Campelo, Jesús Corral, et al. · Clinical & Translational Oncology
PDF
12P Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)
2023 · M. Peressini, C. Martí Cubells, et al. · Immuno-Oncology Technology
PDF
Works count: 38
Citation count: 1,472
H-index: 8
I10-index: 7
Year
Topic
Type